🔎 Trials Near Me

Home › Overactive Bladder › NCT06511141

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Recruiting

Sacral Neuromodulation for Male Overactive Bladder

Who can join

Ages 18 and older · Men

Full eligibility criteria
Key Inclusion Criteria:

1. Participants aged ≥ 18 years at the time of enrollment
2. Able to complete bladder diaries and patient questionnaires
3. Primary diagnosis of OAB (urinary urgency incontinence (UUI) or urinary frequency (UF)).
4. Willing and capable to provide written informed consent and agrees to comply with specified evaluations at clinical investigational sites and attend all follow-up assessments for up to 1 year

Key Exclusion Criteria:

1. Any patient that is not a suitable candidate per investigator discretion
2. Recent prostate therapy or procedure within the last 6 months at the time of enrollment
3. Any neurological condition that could interfere with normal bladder function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or spinal cord injury (e.g., paraplegia)
4. Previously implanted with a sacral neuromodulation device, including inactive SNM devices
5. Any prior treatment with an Implantable Tibial Nerve Stimulation (ITNS)
6. Positive response to Percutaneous Tibial Nerve Stimulation (PTNS) within the last 3 months at the time of enrollment
7. Underwent an external trial with any sacral neuromodulation device and was deemed a non-responder by a physician
8. Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study objectives at the discretion of the participating physician.
9. Uncontrolled diabetes
10. Known allergic reactions to components of the Axonics SNM System, including titanium, zirconia, polyurethane, epoxy, or silicone

About the study

To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

What is being tested

Sponsor: Axonics, Inc. · Participants: 150 · Started: Oct 22, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06511141

Locations in the U.S.

AlabamaUniversity of Alabama at Birmingham, Birmingham
ArizonaMayo Clinic, Scottsdale
CaliforniaUSNC, Mountain View
Tri Valley Urology, Murrieta
University of California San Francisco, San Francisco
FloridaUniversity of Miami, Miami
AdventHealth, Orlando
Advanced Urology Institute, Oxford
LouisianaLouisiana State University, New Orleans
WK Clinical Research, Shreveport
MarylandAnne Arundel Urology, Annapolis
MichiganWayne State University, Detroit
MinnesotaMayo Clinic, Rochester
New YorkIntegrated Medical Professionals, New York
North CarolinaAssociated Urologists of North Carolina (AUNC), Raleigh
OhioUniversity Hospitals Cleveland, Cleveland
OklahomaUtica Park Urology, Tulsa
PennsylvaniaMidLantic Urology, Bala-Cynwyd
South CarolinaLowcountry Urology Clinics, North Charleston
TexasUrology Partners of North Texas (UPNT), Arlington
VirginiaPotomac Urology, Woodbridge

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.